Welcome to our dedicated page for DURECT SEC filings (Ticker: DRRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The DURECT Corporation (DRRX) SEC filings page on Stock Titan provides access to historical regulatory documents filed by this former Nasdaq-listed biopharmaceutical company. These filings trace DURECT’s evolution as a late-stage developer of epigenetic therapies, its financial reporting as a public issuer, and the steps that led to its acquisition by a subsidiary of Bausch Health Americas, Inc. and subsequent delisting.
For users analyzing DURECT’s business, earlier periodic reports and current reports on Form 8-K describe the company’s focus on larsucosterol, an investigational epigenetic modulator in clinical development for alcohol-associated hepatitis (AH), and disclose that the U.S. Food and Drug Administration granted larsucosterol Fast Track and Breakthrough Therapy designations for this indication. Other filings reference the company’s FDA-approved non-opioid analgesic POSIMIR, based on its SABER platform technology, and the sale of the ALZET osmotic pump product line.
Later filings are particularly important for understanding DRRX’s trading and registration status. A series of Forms 8-K in 2025 describe the Agreement and Plan of Merger with Bausch Health Americas, Inc., the commencement and terms of the tender offer for all outstanding DURECT shares, amendments to the merger agreement, and the completion of the merger on September 11, 2025. A Form 25 filed by The Nasdaq Stock Market LLC on that date documents the removal of DURECT’s common stock from listing on Nasdaq. Subsequently, a Form 15 filed on September 22, 2025 certifies the termination of registration of the common stock under Section 12(g) of the Exchange Act and the suspension of DURECT’s duty to file reports under Sections 13 and 15(d).
On Stock Titan, these filings are accompanied by AI-generated highlights that help explain key sections, such as change-of-control terms in merger-related 8-Ks, delisting notices, and the implications of Form 15 deregistration. Users can quickly identify documents related to corporate transactions, historical financial condition, and the regulatory history of larsucosterol and POSIMIR, while still having direct access to the full text as filed with the SEC.
Durect Corporation filed an S-8 registration post-effective submission listing numerous prior S-8 registration statements and the share authorizations under its employee and director plans. The filing records repeated registrations dating from October 5, 2000 through November 14, 2024, including a recent registration of 2,000,000 shares under the 2000 Stock Plan (post 1-for-10 reverse split) and multiple Employee Stock Purchase Plan registrations.
Durect Corporation (DRRX) filed an S-8 post-effective amendment listing numerous prior S-8 registration statements and documenting serial registrations of Common Stock for employee plans from 2000 through November 14, 2024. The filing explicitly registers specific share amounts under the 1998 Incentive Stock Plan, the 2000 Employee Stock Purchase Plan, the 2000 Stock Plan and the 2000 Directors' Stock Option Plan across multiple dates. The document also notes a 1-for-10 reverse stock split of common stock effected on December 5, 2022.
Durect Corporation (DRRX) filed an S-8 post-effective amendment listing a series of prior S-8 registration statements and updating share counts under employee plans. The filing documents multiple historical registrations under the 2000 Stock Plan and the Employee Stock Purchase Plan, and specifically registers 2,000,000 shares of Common Stock under the 2000 Stock Plan (after a 1-for-10 reverse stock split effected December 5, 2022). The document is administrative, reflecting reserved shares for employee compensation plans rather than operating results.
Durect Corporation filed an S-8 post-effective submission listing numerous prior S-8 registration statements and detailing shares reserved under various employee plans. The filing itemizes historical registrations by date and plan, including registrations for the 1998 Incentive Stock Plan, the 2000 Employee Stock Purchase Plan (as amended), the 2000 Stock Plan (as amended), the 2000 Directors' Stock Option Plan and legacy Southern BioSystems and Southern Research Technologies option plans. The filing notes a 1-for-10 reverse stock split effected December 5, 2022, and is signed by CFO Timothy M. Papp.
Durect Corporation filed an S-8 post-effective submission listing multiple prior S-8 registration statements covering employee equity plans and employee stock purchase plans, with specific historical filings and share amounts from 2000 through November 14, 2024. The filing notes a 1-for-10 reverse stock split of common stock effected December 5, 2022, and is signed by CFO Timothy M. Papp.
Durect Corporation (DRRX) submitted an S-8 post-effective amendment registering employee equity under multiple prior S-8 filings. The filing lists numerous prior S-8 registration statements and specifies shares registered under various company plans: Employee Stock Purchase Plan allocations typically of 225,000–350,000 shares in multiple years, large annual allocations to the 2000 Stock Plan (ranging from 2,250,000 to 18,000,000 in certain years), and smaller allocations under Directors' and other option plans. The filing also states a 1-for-10 reverse stock split of common stock effected December 5, 2022.
Durect Corporation (DRRX) submitted a posteffective S-8 registration covering multiple employee plans and lists prior S-8 registrations dating back to 2000. The filing registers shares for several equity plans including the 1998 Incentive Stock Plan, the 2000 Employee Stock Purchase Plan (as amended), the 2000 Stock Plan (as amended) and the 2000 Directors' Stock Option Plan, with specific historical registrations and share amounts noted. The filing also records a 1-for-10 reverse stock split effected on December 5, 2022.
Durect Corporation (DRRX) files an S-8 post-effective amendment listing historical employee equity registrations and a recent reverse stock split. The filing itemizes numerous prior S-8 registrations dating from October 5, 2000 through November 14, 2024 covering employee stock purchase plan shares, stock option plan shares and director option plan shares with amounts ranging from tens of thousands to multi‑million share authorizations (examples: 18,000,000 shares registered on August 5, 2022; 5,500,000 on August 5, 2011). The document also notes a 1‑for‑10 reverse stock split of common stock effected December 5, 2022.
FAQ
What is the current stock price of DURECT (DRRX)?
What is the market cap of DURECT (DRRX)?
